JPWO2020053833A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020053833A5
JPWO2020053833A5 JP2021514336A JP2021514336A JPWO2020053833A5 JP WO2020053833 A5 JPWO2020053833 A5 JP WO2020053833A5 JP 2021514336 A JP2021514336 A JP 2021514336A JP 2021514336 A JP2021514336 A JP 2021514336A JP WO2020053833 A5 JPWO2020053833 A5 JP WO2020053833A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
inhibitor
antibody
pparβ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021514336A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500448A5 (https=
JP2022500448A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/057745 external-priority patent/WO2020053833A1/en
Publication of JP2022500448A publication Critical patent/JP2022500448A/ja
Publication of JPWO2020053833A5 publication Critical patent/JPWO2020053833A5/ja
Publication of JP2022500448A5 publication Critical patent/JP2022500448A5/ja
Priority to JP2024124104A priority Critical patent/JP2024153816A/ja
Pending legal-status Critical Current

Links

JP2021514336A 2018-09-14 2019-09-13 制御性ｔ細胞を調節し腫瘍増殖を阻害する方法 Pending JP2022500448A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024124104A JP2024153816A (ja) 2018-09-14 2024-07-31 制御性ｔ細胞を調節し腫瘍増殖を阻害する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862731351P 2018-09-14 2018-09-14
US62/731,351 2018-09-14
PCT/IB2019/057745 WO2020053833A1 (en) 2018-09-14 2019-09-13 Methods for modulating regulatory t cells and inhibiting tumor growth

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024124104A Division JP2024153816A (ja) 2018-09-14 2024-07-31 制御性ｔ細胞を調節し腫瘍増殖を阻害する方法

Publications (3)

Publication Number Publication Date
JP2022500448A JP2022500448A (ja) 2022-01-04
JPWO2020053833A5 true JPWO2020053833A5 (https=) 2022-08-29
JP2022500448A5 JP2022500448A5 (https=) 2022-08-29

Family

ID=68393033

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021514336A Pending JP2022500448A (ja) 2018-09-14 2019-09-13 制御性ｔ細胞を調節し腫瘍増殖を阻害する方法
JP2024124104A Pending JP2024153816A (ja) 2018-09-14 2024-07-31 制御性ｔ細胞を調節し腫瘍増殖を阻害する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024124104A Pending JP2024153816A (ja) 2018-09-14 2024-07-31 制御性ｔ細胞を調節し腫瘍増殖を阻害する方法

Country Status (7)

Country Link
US (1) US20220049010A1 (https=)
EP (1) EP3849666B1 (https=)
JP (2) JP2022500448A (https=)
CN (2) CN121534175A (https=)
AU (2) AU2019340475B2 (https=)
CA (1) CA3109563A1 (https=)
WO (1) WO2020053833A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2990885A1 (en) 2015-06-30 2017-01-05 Sanford-Burnham Medical Research Institute Btla fusion protein agonists and uses thereof
CN112168820B (zh) * 2019-07-05 2023-09-29 中国科学院生物物理研究所 SRCAP ATPase抑制剂在结直肠癌治疗中的应用
WO2021152548A1 (en) * 2020-01-30 2021-08-05 Benitah Salvador Aznar Combination therapy for treatment of cancer and cancer metastasis
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO20004844L (no) * 2000-09-27 2002-05-10 Thia Medica As Fettsyre analoger for behandling av proliferative hudsykdommer
KR20070022197A (ko) * 2003-11-05 2007-02-26 팔링겐, 인코포레이티드 Ｃｄｉｍ 결합 항체의 증강된 ｂ 세포 세포독성
JP2008521814A (ja) * 2004-11-24 2008-06-26 シェーリング コーポレイション Ｄａｐ−１０およびその使用
JP2012149004A (ja) * 2011-01-18 2012-08-09 Theravalues Corp 核内受容体の賦活剤
CA2988119A1 (en) * 2015-06-03 2016-12-08 Dana-Farber Cancer Institute, Inc. Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy
EP3650468A1 (en) * 2015-09-29 2020-05-13 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Targeting metastasis stem cells through a fatty acid receptor (cd36)
WO2018029336A1 (en) * 2016-08-12 2018-02-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
GB201802307D0 (en) * 2018-02-13 2018-03-28 Vib Vzw CD36 antagonists for use in melanoma treatment

Similar Documents

Publication Publication Date Title
US12364714B2 (en) Methods for selective expansion of gamma delta t-cell populations and compositions thereof
Zhang et al. Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy
JP2022500448A5 (https=)
Chang et al. Combination therapy with bispecific antibodies and PD-1 blockade enhances the antitumor potency of T cells
JP7573441B2 (ja) ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
HRP20211333T1 (hr) Molekule za vezanje pd-1 i lag-3 i postupci za njihovu uporabu
JP2019500891A5 (https=)
JP2019521645A5 (https=)
JP2018503365A5 (https=)
JP2019513725A5 (https=)
JP2019500892A5 (https=)
JP2018520650A5 (https=)
JP2016525117A5 (https=)
RU2018135247A (ru) БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К CD25 И Fc ГАММА-РЕЦЕПТОРУ ДЛЯ ЭЛИМИНАЦИИ ОПУХОЛЕСПЕЦИФИЧЕСКИХ КЛЕТОК
JPWO2020135201A5 (https=)
HRP20221226T1 (hr) Protutijela protiv pd-1 i postupci njihove upotrebe
JP2017506067A5 (https=)
JP2018525382A5 (https=)
JP2018509175A5 (https=)
JP2020512973A5 (https=)
JP2019525957A5 (https=)
JP2020502147A5 (https=)
WO2017040666A4 (en) Combination therapy for treatment of disease
JP2021501801A5 (https=)
JP2021520201A5 (https=)